AU718436B2 - Synthetic peptides and pharmaceutical compositions comprising them - Google Patents

Synthetic peptides and pharmaceutical compositions comprising them Download PDF

Info

Publication number: AU718436B2
Authority: AU; Australia
Prior art keywords: peptide; seq; amino acid; response; peptides
Prior art date: 1995-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU59095/96A

Other languages

English (en)

Other versions

AU5909596A (en

Inventor

Edna Mozes

Michael Sela

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-06

Publication date

2000-04-13

1996-06-06 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

1996-12-30 Publication of AU5909596A publication Critical patent/AU5909596A/en

2000-04-13 Application granted granted Critical

2000-04-13 Publication of AU718436B2 publication Critical patent/AU718436B2/en

2016-06-06 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 226
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 88
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
206010028417 myasthenia gravis Diseases 0.000 claims abstract description 64
230000009696 proliferative response Effects 0.000 claims abstract description 53
238000006467 substitution reaction Methods 0.000 claims abstract description 47
125000000539 amino acid group Chemical group 0.000 claims abstract description 25
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
108010009685 Cholinergic Receptors Proteins 0.000 claims abstract description 13
102000034337 acetylcholine receptors Human genes 0.000 claims abstract description 13
210000001744 T-lymphocyte Anatomy 0.000 claims description 71
150000001413 amino acids Chemical class 0.000 claims description 60
230000002401 inhibitory effect Effects 0.000 claims description 55
230000004044 response Effects 0.000 claims description 44
238000000034 method Methods 0.000 claims description 13
230000008859 change Effects 0.000 claims description 9
230000002209 hydrophobic effect Effects 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
206010028372 Muscular weakness Diseases 0.000 claims description 2
238000011160 research Methods 0.000 claims description 2
229960000814 tetanus toxoid Drugs 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims 3
229920001577 copolymer Polymers 0.000 claims 1
235000013882 gravy Nutrition 0.000 claims 1
230000036473 myasthenia Effects 0.000 claims 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 73
235000001014 amino acid Nutrition 0.000 description 61
229940024606 amino acid Drugs 0.000 description 56
230000005764 inhibitory process Effects 0.000 description 38
230000009977 dual effect Effects 0.000 description 34
210000001165 lymph node Anatomy 0.000 description 29
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 28
241000699670 Mus sp. Species 0.000 description 27
230000000694 effects Effects 0.000 description 27
210000000612 antigen-presenting cell Anatomy 0.000 description 19
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 17
238000011725 BALB/c mouse Methods 0.000 description 16
238000012360 testing method Methods 0.000 description 14
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 13
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
108091054438 MHC class II family Proteins 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
238000001727 in vivo Methods 0.000 description 11
239000000203 mixture Substances 0.000 description 11
-1 thymectomy Substances 0.000 description 11
238000000338 in vitro Methods 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 9
208000023275 Autoimmune disease Diseases 0.000 description 9
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 9
BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000011534 incubation Methods 0.000 description 9
108010079317 prolyl-tyrosine Proteins 0.000 description 9
229940104230 thymidine Drugs 0.000 description 9
ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 8
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000003556 assay Methods 0.000 description 8
108010090894 prolylleucine Proteins 0.000 description 8
230000004936 stimulating effect Effects 0.000 description 8
VDHOMPFVSABJKU-ULQDDVLXSA-N His-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N VDHOMPFVSABJKU-ULQDDVLXSA-N 0.000 description 7
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 7
DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 7
108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 7
DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 7
230000004913 activation Effects 0.000 description 7
238000011081 inoculation Methods 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
102000043131 MHC class II family Human genes 0.000 description 5
241001529936 Murinae Species 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
125000001165 hydrophobic group Chemical group 0.000 description 5
230000006698 induction Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
230000006472 autoimmune response Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000006287 biotinylation Effects 0.000 description 4
238000007413 biotinylation Methods 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000037452 priming Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
108010092114 histidylphenylalanine Proteins 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
235000019766 L-Lysine Nutrition 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 2
WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 2
OXHSZBRPUGNMKW-DCAQKATOSA-N Met-Gln-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OXHSZBRPUGNMKW-DCAQKATOSA-N 0.000 description 2
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
GNZCMRRSXOBHLC-JYJNAYRXSA-N Phe-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N GNZCMRRSXOBHLC-JYJNAYRXSA-N 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
ABCLYRRGTZNIFU-BWAGICSOSA-N Thr-Tyr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O ABCLYRRGTZNIFU-BWAGICSOSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000036982 action potential Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229920005605 branched copolymer Polymers 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229920005684 linear copolymer Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000001538 myasthenic effect Effects 0.000 description 2
230000002232 neuromuscular Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
108010073969 valyllysine Proteins 0.000 description 2
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 1
WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 description 1
NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 1
GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 1
JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
VDCRBJACQKOSMS-JSGCOSHPSA-N Gly-Phe-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O VDCRBJACQKOSMS-JSGCOSHPSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
108010070562 HLA-DR5 Antigen Proteins 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 1
WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
YWCJXQKATPNPOE-UKJIMTQDSA-N Ile-Val-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N YWCJXQKATPNPOE-UKJIMTQDSA-N 0.000 description 1
NJGXXYLPDMMFJB-XUXIUFHCSA-N Ile-Val-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N NJGXXYLPDMMFJB-XUXIUFHCSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
241001435619 Lile Species 0.000 description 1
SBSIKVMCCJUCBZ-GUBZILKMSA-N Met-Asn-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N SBSIKVMCCJUCBZ-GUBZILKMSA-N 0.000 description 1
SQUTUWHAAWJYES-GUBZILKMSA-N Met-Asp-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SQUTUWHAAWJYES-GUBZILKMSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101150076359 Mhc gene Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
235000021186 dishes Nutrition 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010049041 glutamylalanine Proteins 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000007365 immunoregulation Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
239000012985 polymerization agent Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108010031719 prolyl-serine Proteins 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
229960002290 pyridostigmine Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)

AU59095/96A 1995-06-07 1996-06-06 Synthetic peptides and pharmaceutical compositions comprising them Ceased AU718436B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/475577		1995-06-07
US08/475,577 US6066621A (en)	1989-12-10	1995-06-07	Synthetic peptides for the treatment of myasthenia gravis
PCT/IL1996/000005 WO1996040777A2 (fr)	1995-06-07	1996-06-06	Peptides synthetiques et compositions pharmaceutiques contenant ces peptides

Publications (2)

Publication Number	Publication Date
AU5909596A AU5909596A (en)	1996-12-30
AU718436B2 true AU718436B2 (en)	2000-04-13

Family

ID=23888200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU59095/96A Ceased AU718436B2 (en)	1995-06-07	1996-06-06	Synthetic peptides and pharmaceutical compositions comprising them

Country Status (9)

Country	Link
US (1)	US6066621A (fr)
EP (1)	EP0832127B1 (fr)
JP (1)	JP4065322B2 (fr)
AT (1)	ATE192164T1 (fr)
AU (1)	AU718436B2 (fr)
CA (1)	CA2221646A1 (fr)
DE (1)	DE69607962T2 (fr)
IL (1)	IL122443A (fr)
WO (1)	WO1996040777A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6911526B2 (en) *	1996-07-22	2005-06-28	The Trustees Of Columbia University In The City Of New York	Compounds that inhibit the interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
WO2000005249A2 (fr)	1998-07-23	2000-02-03	The President And Fellows Of Harvard College	Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
CA2405484A1 (fr) *	2000-03-31	2001-10-11	Corixa Corporation	Identification de peptides immunodominants potentiels de sous-unites alpha du recepteur de l'acetylcholine
US7273722B2 (en) *	2000-11-29	2007-09-25	Allergan, Inc.	Neurotoxins with enhanced target specificity
IL141647A0 (en) *	2001-02-26	2002-03-10	Yeda Res & Dev	Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
WO2022260579A2 (fr)	2021-06-07	2022-12-15	Toleranzia Ab	Protéine de fusion dans la myasthénie grave
TW202444434A (zh) *	2023-03-24	2024-11-16	美商庫爾製藥發展公司股份有限公司	用於重症肌無力治療之免疫修飾奈米粒子之處理

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340012C (fr) *	1987-08-17	1998-08-25	Trustees Of Leland Stanford Jr. University	Determinant peptidique associe a l'immunite
IL92629A0 (en) *	1989-12-10	1990-08-31	Yeda Res & Dev	Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US5116944A (en) *	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
IL122445A0 (en) *	1992-06-18	1998-06-15	Yeda Res & Dev	Peptide polymers and pharmaceutical compositions comprising them for treatment of myasthenia gravis

1995
- 1995-06-07 US US08/475,577 patent/US6066621A/en not_active Expired - Fee Related
1996
- 1996-06-06 DE DE69607962T patent/DE69607962T2/de not_active Expired - Fee Related
- 1996-06-06 EP EP96916286A patent/EP0832127B1/fr not_active Expired - Lifetime
- 1996-06-06 IL IL122443A patent/IL122443A/en not_active IP Right Cessation
- 1996-06-06 WO PCT/IL1996/000005 patent/WO1996040777A2/fr not_active Ceased
- 1996-06-06 CA CA002221646A patent/CA2221646A1/fr not_active Abandoned
- 1996-06-06 AT AT96916286T patent/ATE192164T1/de not_active IP Right Cessation
- 1996-06-06 AU AU59095/96A patent/AU718436B2/en not_active Ceased
- 1996-06-06 JP JP50029497A patent/JP4065322B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1996040777A3 (fr)	1997-01-23
EP0832127B1 (fr)	2000-04-26
US6066621A (en)	2000-05-23
JP4065322B2 (ja)	2008-03-26
DE69607962T2 (de)	2000-12-07
DE69607962D1 (de)	2000-05-31
EP0832127A2 (fr)	1998-04-01
WO1996040777A2 (fr)	1996-12-19
IL122443A0 (en)	1998-06-15
CA2221646A1 (fr)	1996-12-19
JPH11507620A (ja)	1999-07-06
IL122443A (en)	2007-10-31
AU5909596A (en)	1996-12-30
ATE192164T1 (de)	2000-05-15

Legal Events

Date	Code	Title	Description
2000-08-10	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
US5679640A (en)	1997-10-21	Immunosuppressant peptides
US8198401B2 (en)	2012-06-12	Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis
IE912701A1 (en)	1992-02-12	Novel immunosuppressant peptides
EP3301107A1 (fr)	2018-04-04	Nouveaux peptides qui se lient à des types de cmh (complexe majeur d'histocompatibilité) de classe ii et leur utilisation en vue de diagnostic et de traitement
Myers et al.	1993	A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis
JP3468528B2 (ja)	2003-11-17	ペプチド誘導体
AU8035200A (en)	2001-04-24	Hybrid peptides modulate the immune response
AU718436B2 (en)	2000-04-13	Synthetic peptides and pharmaceutical compositions comprising them
US7122193B1 (en)	2006-10-17	Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis
Diab et al.	1999	Human collagen II peptide 256–271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis
CA2138258C (fr)	2003-08-19	Pepitides synthetiques pour le traitement de la myasthenie grave
US20070161545A1 (en)	2007-07-12	Triple polypeptide complexes
CA2194548A1 (fr)	1996-01-25	Composes de peptide de pro-insuline utiles pour detecter et traiter le diabete du type i
EP0972032B1 (fr)	2006-12-20	Peptides destines au traitement du lupus erythemateux systemique
Holm et al.	2006	Side-chain and backbone amide bond requirements for glycopeptide stimulation of T-cells obtained in a mouse model for rheumatoid arthritis
AU780238B2 (en)	2005-03-10	Modified peptides and peptidomimetics for use in immunotherapy
US6716811B1 (en)	2004-04-06	Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
JPH10511985A (ja)	1998-11-17	ヒトグルタミン酸デカルボキシラーゼ（ｇａｄ）からの自己反応性ペプチド
CA2421321A1 (fr)	2004-09-07	Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide
Kanagawa et al.	1997	The role of I-Ag7 beta chain in peptide binding and antigen recognition by T cells.
KR20000070542A (ko)	2000-11-25	Ⅱ형 콜라겐에 특이적인 ｔ 세포 에피토프를 포함하는 펩티드
US20020037844A1 (en)	2002-03-28	Synthetic peptide for treatment of autoimmune arthritis
JP2002521387A (ja)	2002-07-16	共重合体１および関連する共重合体ならびにペプチドによる自己免疫疾患の治療
CA2295994A1 (fr)	1998-12-23	Peptides et composes se liant au recepteur de l'interleukine 5
CA2394323A1 (fr)	2001-06-21	Peptides et composes se fixant au recepteur il-5